DocMorris AG (CH:DOCM)
:DOCM
Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF6.61
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF6.61
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF8.78
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF347.91M
Enterprise ValueCHF510.92M
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,007,114
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.09Price Target Upside-7.87% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.78
Revenue Forecast (FY)CHF1.21B
Bulls Say, Bears Say
Bulls Say
Digital Services High-margin GrowthRapid 110% growth in Digital Services (TeleClinic + Retail Media) reflects a scalable, high-margin revenue stream that diversifies away from lower-margin Rx/OTC retail. As take-rates and ad/treatment volumes rise, this segment meaningfully boosts CM3 and supports lasting margin expansion and unit economics improvement.
Clear Path To ProfitabilityConcrete guidance to reach EBITDA breakeven in 2026 and FCF breakeven in 2027 demonstrates credible operational levers (CM3 improvement, cost discipline, Digital Services scale). This multi-year plan aligns incentives and capital allocation, improving predictability of long-term cash generation if execution holds.
Improved Leverage And Liquidity PositionMaterial improvement in leverage (debt-to-equity from ~1.51x to ~0.64x) and a CHF160m liquidity buffer provide a clearer runway to execute restructuring and growth plans. Stronger equity ratio increases financial flexibility and lowers immediate refinancing pressure while management addresses cash burn.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained OCF and FCF deficits (materially worse in 2025) indicate structural cash burn that will require either rapid margin improvement or external funding. Persistent negative cash generation constrains reinvestment, increases refinancing reliance, and raises execution risk for the 2026–2027 profitability timeline.
Ongoing Operating Losses And Weak MarginsConsecutive years of negative net margins and deteriorating gross profit point to structural profitability challenges. Negative returns reduce retained-capital generation, limit strategic optionality, and increase sensitivity to cost and volume shocks, making consistent margin recovery essential for long-term viability.
Logistics, Working-capital And Refinancing RisksRising logistics costs, inventory overstocking and receivable slippage materially erode free cash flow and margins. Combined with a sizeable convertible maturity later in the cycle, these operational and financing frictions create a durable headwind that could force higher prices, margin concessions, or additional funding if efficiencies aren't delivered.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF8.78 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF347.91M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 76 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Overvalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,007,114 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products, as well as medicines management services. It also operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals under the Zur Rose, PromoFarma, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
DOCM Stock 12 Month Forecast
Average Price Target
CHF6.09
▼(-7.87% Downside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―
Options Prices
Currently, No data available
---